There are 2934 resources available
What is today’s understanding of the molecular landscape of advanced urothelial carcinoma?
Presenter: Eva Comperat
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?
Resources:
Webcast
How could targeted therapies influence the management landscape?
Presenter: Yohann Loriot
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?
Resources:
Webcast
Can the molecular biology knowledge be integrated into the clinical practice today?
Presenter: Arlene Siefker-Radtke
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?
Resources:
Webcast
Advanced urothelial carcinoma 2.0: Are we ready for a paradigm shift? Closing remarks
Presenter: Maria De Santis
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?
Resources:
Webcast
Introduction: Welcome to the future?
Presenter: Joaquim Bellmunt
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?
Resources:
Webcast
The path to now: How did the current management of advanced urothelial carcinoma develop?
Presenter: Shahrokh F. Shariat
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?
Resources:
Webcast
2801 - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
EONS - Leadership, combining research with daily practice
Presenter: Hester Vermeulen
Session: EONS 12: Opening session
Resources:
Slides
Webcast
811 - ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat (tela; CB-839) + everolimus (E) vs. placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
Presenter: Chung-Han Lee
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1900 - Initial Results From TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients (Pts) With Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimens (PLT) or Immunotherapy
Presenter: Scott Tagawa
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast